ALISO VIEJO, Calif., July 19 /PRNewswire-FirstCall/ -- Clarient, Inc. , a technology and services resource for pathologists, oncologists and the pharmaceutical industry, will report its 2006 second quarter results after the stock market closes on Wednesday, August 2, 2006. That same day management will host a conference call at 5:00 p.m. (EDT) to discuss results of operations.
Listeners may access the call by dialing 1-877-704-5384 or 1-913-312-1297 for international callers. A webcast will also be available through the Clarient company website at www.clarientinc.com/investor. For those unable to participate in the call, a replay will be available by dialing 1-888-203-1112 or 1-719-457-0820 for international callers, password 9087471. This replay will be accessible from 8:00 p.m. EDT on August 2, 2006 until midnight on August 9, 2006.
About Clarient, Inc.
Clarient (www.clarientinc.com) combines innovative technologies with world class expertise to assess and characterize cancer. Clarient's mission is to provide technologies, services and the critical information to improve the quality and reduce the cost of patient care as well as accelerating the drug development process. The Company's principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies.
The company was formed in 1996 to develop and market the ACIS(R) Automated Cellular Imaging System, an important advance in slide-based testing. The rise of individualized medicine as the new direction in oncology led the company in 2004 to expand its business model to provide the full range of leading diagnostic technologies such as flow cytometry and molecular testing in-house, creating a state-of-the-art commercial cancer laboratory and providing the most advanced oncology testing and drug development services available. For more information, visit www.clarientinc.com.
About Safeguard
Safeguard Scientifics, Inc. builds value in high-growth, revenue-stage information technology and life sciences businesses. Safeguard provides growth capital as well as a range of strategic, operating and management resources to our partner companies. The company participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. For more information about Safeguard, please visit www.safeguard.com.
The statements herein regarding Clarient, Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the Company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to the Company's ability to regain compliance with the Nasdaq minimum bid price requirement and to maintain compliance with other Nasdaq continued listing criteria, the potential delisting from the Nasdaq Capital Market and other risks detailed from time to time in the Company's SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to instrument placements, new contracts for placements, revenues and results of operations may not be indicative of future results for the reasons set forth above.
The company does not assume any obligation to update any forward-looking statements or other information contained in this document.
Contact: Charlene Lu Clarient, Inc. (203) 682 8268 charlene.lu@icrinc.com
Clarient, Inc.CONTACT: Charlene Lu of Clarient, Inc., +1-203-682-8268,charlene.lu@icrinc.com
